和黃醫藥盤前漲超1% 完成HMPL-453(fanregratinib)用於治療肝內膽管癌的中國II期註冊研究的患者入組

Breakings · 09:16

和黃醫藥(HCM.US)盤前漲1.36%，報15.7美元。和黃醫藥近日公告，HMPL-453(fanregratinib)用於治療伴有成纖維細胞生長因數受體(FGFR)2融合/重排的肝內膽管癌患者的II期臨牀試驗已完成患者入組。研究的首名患者於2023年3月接受首次給藥治療，和黃醫藥預計將在2025年年底左右公佈該研究的頂線結果。若取得積極結果，將支持向中國國家藥品監督管理局提交新藥上市申請。

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Recommended

US stock market outlook | February PPI and initial unemployment claims were lower than expected! The decline in the three majo…

Futu News · Mar 13, 2025 12:48
The USA PPI has reached its smallest month-on-month increase since July, is the "Federal Reserve Put Options" getting closer to…

Zhitong Finance · Mar 13, 2025 14:00
Senate Democrats oppose the temporary spending bill, and the USA government is set to shut down on Friday without a doubt.

wallstreetcn · Mar 13, 2025 13:23
Trump undermines faith in the U.S. stock market bull run! Under the shadow of the trade war, calls for "bargain hunting" on Wall…

Zhitong Finance · Mar 13, 2025 14:51
JPMorgan: The recent decline in U.S. stocks has "reached its point," and a steady recovery is highly likely moving forward.

wallstreetcn · Mar 13, 2025 12:46

Write a comment

和黄医药盘前涨超1% 完成HMPL-453(fanregratinib)用于治疗肝内胆管癌的中国II期注册研究的患者入组

和黃醫藥盤前漲超1% 完成HMPL-453(fanregratinib)用於治療肝內膽管癌的中國II期註冊研究的患者入組

Risk Disclaimer

Statement